Examining muscle function in patients with interstitial lung disease
Investigating the Role of Skeletal Muscle Dysfunction on Dyspnea and Exercise Intolerance in Interstitial Lung Disease
This study tests how muscle function affects breathing and exercise in people with interstitial lung disease compared to healthy individuals, and looks at how supplemental oxygen might help.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 40 Years to 80 Years |
| Sex | All |
| Sponsor | University of British Columbia Academic / other |
| Drugs / interventions | prednisone |
| Locations | 1 site (Vancouver, British Columbia) |
| Trial ID | NCT03800017 on ClinicalTrials.gov |
What this trial studies
This study investigates the relationship between skeletal muscle function and symptoms like dyspnea and exercise intolerance in patients with interstitial lung disease (ILD). It aims to compare the muscle function of ILD patients to healthy controls, assess how muscle fatigue affects their breathing and exercise capacity, and evaluate the impact of supplemental oxygen on these factors. By understanding these dynamics, the study seeks to provide insights into the role of muscle dysfunction in ILD and its effects on patient quality of life.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 40-80 with a diagnosis of interstitial lung disease and specific pulmonary function criteria.
Not a fit: Patients with significant cardiovascular disease or contraindications to exercise testing may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for patients with interstitial lung disease, enhancing their exercise tolerance and overall quality of life.
How similar studies have performed: While the specific approach of this study may be novel, previous studies have indicated that muscle dysfunction can significantly impact patients with chronic respiratory diseases.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria for ILD Patients: * Age 40-80 years (inclusive) * A multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF), idiopathic fibrotic nonspecific interstitial pneumonia (NSIP), chronic hypersensitivity pneumonitis (HP), or unclassifiable ILD with a differential diagnosis that consists of the above diagnoses * Fibrosis on high resolution computed tomography (HRCT): honeycombing, reticulation, or traction bronchiectasis * Appropriate candidate for pulmonary rehabilitation * 6 minute walk distance 50m or more * Oxygen saturation ≥ 92% by pulse oximetry at rest while breathing room air * Clinically stable for the preceding 6 weeks * Can fluently read and write in English Inclusion Criteria for Healthy Controls: * Age 40-80 (inclusive) * Normal pulmonary function (80-120% predicted) * No lung or cardiovascular disease * Can fluently read and write in English Exclusion Criteria for the ILD patients: * Contraindication to exercise testing (e.g. significant cardiovascular, musculoskeletal, neurological disease) * Other significant extra-pulmonary disease that, based on clinical assessment, could impair exercise capacity and/or oxygenation * Forced vital capacity (FVC) less than 50% or Diffusion capacity for carbon monoxide (DLCO) less than 25% * Concurrent or recent participation (less than 6 months) in a pulmonary rehabilitation program * Use of prednisone greater than 10 mg/day for more than 2 weeks within 3 months of the first study visit * Significant emphysema (less than 10% volume on HRCT or FEV1/FVC less than 0.70) Exclusion Criteria for Healthy Controls: * Currently smoking or previously smoked more than 10 pack-years * Any medical conditions that prevents them for exercising safely * Cardiac pacemaker or any metal or electronic inside the body
Where this trial is running
Vancouver, British Columbia
- St. Paul's Hospital — Vancouver, British Columbia, Canada (Recruiting)
Study contacts
- Principal investigator: Jordan A Guenette, PhD — University of British Columbia
- Study coordinator: Olivia Ferguson, MSc
- Email: Olivia.Ferguson@hli.ubc.ca
- Phone: 1-604-806-8835
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.